68Ga-prostate-specific membrane antigen (PSMA) and 68Ga-DOTA0-Tyr3-octreotate (DOTATATE) positron emission tomography/computed tomography (PET/CT) in a case of metastatic castration-resistant prostate cancer (mCRPC) with low prostate-specific antigen (PSA) and reduced 18F-fluorodeoxyglucose (FDG) uptake after endocrine therapy
机构：[1]Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China.[2]Department of Nuclear Medicine, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China.[3]Institute of Nuclear Medicine, Southwest Medical University, Luzhou, China.[4]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.[5]Institute of Oncology, Southwest Medical University, Luzhou, China.
A 58-year-old man presented with low back pain and elevated
serum prostate-specific antigen (PSA) (24.7 ng/mL, reference
<4 ng/mL). Prostate biopsy confirmed a diagnosis of poorly
differentiated adenocarcinoma (Gleason score: 10, World
Health Organization/International Society of Urological
Pathology group: 5). A baseline 18F-fluorodeoxyglucose
(FDG) positron emission tomography/computed tomography
(PET/CT) scan was performed for initial staging, and the
maximum intensity projection (MIP) image revealed multiple
tumor lesions throughout the body (Figure 1A). The patient
was diagnosed with metastatic hormone-sensitive prostate
cancer, and received goserelin combined with abiraterone
acetate and dexamethasone as the first-line therapy.
基金：
the Scientific Research Foundation for Doctors of the Affiliated Hospital
of Southwest Medical University (No. 20016) and the
Science and Technology Project founded by Southwest
Medical University (No. 2018-ZRZD-016); and the
Sichuan Provincial Department of Science and Technology
(No. 2022YFQ0099).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类|3 区医学
小类|3 区核医学
最新[2025]版：
大类|3 区医学
小类|3 区核医学
第一作者：
第一作者机构：[1]Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China.[2]Department of Nuclear Medicine, Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China.[3]Institute of Nuclear Medicine, Southwest Medical University, Luzhou, China.
通讯作者：
通讯机构：[4]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.[5]Institute of Oncology, Southwest Medical University, Luzhou, China.
推荐引用方式(GB/T 7714)：
Li Linwei,Chen Yue,Zou Linglin.68Ga-prostate-specific membrane antigen (PSMA) and 68Ga-DOTA0-Tyr3-octreotate (DOTATATE) positron emission tomography/computed tomography (PET/CT) in a case of metastatic castration-resistant prostate cancer (mCRPC) with low prostate-specific antigen (PSA) and reduced 18F-fluorodeoxyglucose (FDG) uptake after endocrine therapy[J].Quantitative Imaging In Medicine And Surgery.2025,15(10):10341-10345.doi:10.21037/qims-24-1475.
APA：
Li Linwei,Chen Yue&Zou Linglin.(2025).68Ga-prostate-specific membrane antigen (PSMA) and 68Ga-DOTA0-Tyr3-octreotate (DOTATATE) positron emission tomography/computed tomography (PET/CT) in a case of metastatic castration-resistant prostate cancer (mCRPC) with low prostate-specific antigen (PSA) and reduced 18F-fluorodeoxyglucose (FDG) uptake after endocrine therapy.Quantitative Imaging In Medicine And Surgery,15,(10)
MLA：
Li Linwei,et al."68Ga-prostate-specific membrane antigen (PSMA) and 68Ga-DOTA0-Tyr3-octreotate (DOTATATE) positron emission tomography/computed tomography (PET/CT) in a case of metastatic castration-resistant prostate cancer (mCRPC) with low prostate-specific antigen (PSA) and reduced 18F-fluorodeoxyglucose (FDG) uptake after endocrine therapy".Quantitative Imaging In Medicine And Surgery 15..10(2025):10341-10345
